Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 40
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06433765 | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) | ||
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | ||
| NCT01767766 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | ||
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | ||
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | ||
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | ||
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | ||
| NCT03277248 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | ||
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | ||
| NCT02535286 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | ||
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | ||
| NCT06143514 | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | ||
| NCT03804996 | Study of TG-1801 in Subjects With B-Cell Lymphoma | ||
| NCT05877963 | Study to Evaluate Efficacy of a Modified Regimen of Ublituximab | ||
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | ||
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | ||
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | ||
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | ||
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | ||
| NCT03776864 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | ||
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | ||
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | ||
| NCT02738775 | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis | ||
| NCT03381170 | An Extension of the TG1101-RMS201 Trial | ||
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | ||
| NCT06433752 | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | ||
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | ||
| NCT02100852 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | ||
| NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | ||
| NCT02006485 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | ||
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | ||
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | ||
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | ||
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | ||
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | ||
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | ||
| NCT03277261 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | ||
| NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ||
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | ||
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL |
